Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 21, 2022; 28(19): 2148-2151
Published online May 21, 2022. doi: 10.3748/wjg.v28.i19.2148
Effects of diabetes type 2 and metformin treatment in Swedish patients with colorectal cancer
Jan Dimberg, Levar Shamoun, Kalle Landerholm, Dick Wågsäter
Jan Dimberg, Department of Natural Science and Biomedicine, School of Health and Welfare, Jönköping University, Jönköping 551 11, Sweden
Levar Shamoun, Department of Laboratory Medicine and Pathology, Region Jönköping County, Jönköping 553 05, Sweden
Levar Shamoun, Dick Wågsäter, Department of Medical Cell Biology, Uppsala University, Uppsala 751 23, Sweden
Kalle Landerholm, Department of Surgery, Region Jönköping County, Jönköping 553 05, Sweden
Kalle Landerholm, Department of Biomedical and Clinical Sciences, Linköping University, Linköping 581 85, Sweden
Author contributions: Dimberg J and Wågsäter D designed and coordinated the study; Shamoun L performed the experiments, and acquired and analysed the data; Dimberg J, Shamoun L, Landerholm K, and Wågsäter D interpreted the data; Landerholm K recruited the patients; Dimberg J, Landerholm K, and Wågsäter D wrote the manuscript; all authors made critical revisions to the manuscript and approved the final version of the article.
Supported by the Medical Research Council of Southeast Sweden, No. FORSS-931897; and the Division of Medical Diagnostics of Region Jönköping County, No. Futurum-970572.
Conflict-of-interest statement: The study was supported by grants from Medical Research Council of Southeast Sweden (FORSS-931897) and Division of Medical Diagnostics (Futurum-970572), Region Jönköping County, Sweden. The funding organizations had no role in the design, management, analysis, interpretation of the data, preparation, review, or approval of the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dick Wågsäter, PhD, Professor, Department of Medical Cell Biology, Uppsala University, D1:3, Husargatan 3, Uppsala 751 23, Sweden. dick.wagsater@mcb.uu.se
Received: December 16, 2021
Peer-review started: December 16, 2021
First decision: January 27, 2022
Revised: February 1, 2022
Accepted: April 9, 2022
Article in press: April 9, 2022
Published online: May 21, 2022
Processing time: 151 Days and 22.2 Hours
Core Tip

Core Tip: Type 2 diabetes mellitus (DM) or metformin treatment does not influence mortality in colorectal cancer (CRC). Type 2 DM or metformin does not influence the levels of inflammatory factors in plasma in patients with CRC. Single nucleotide polymorphisms of insulin-like growth factor binding protein 7 are associated with type 2 DM in patients with CRC.